We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

DataM Intelligence | competitive Intelligence Gene therapies, exon-skipping drugs and next-gen steroids are reshaping Duchenne muscular dys ...

The chief executive of a speciality chemicals giant which is one of only two Yorkshire-headquartered FTSE 100 constituents has told Insider the 100-year-old business is ...

Manufacturers appeared to stop rapidly stockpiling drugs and medical products from Europe in April, even amid the lingering ...

Q4 Results Today May 30, 2025, Highlights: Find all the Q4 results 2025 updates for Apollo Hospitals, Vodafone Idea, Sun TV Network, Bajaj Holdings, Inox Wind Energy, AstraZeneca Pharma and more here.